John Chapman BSc (Hons), PhD, DSc, FESC, is Research Professor at the University of Pierre and Marie Curie, Director Emeritus of the Dyslipidemia and Atherosclerosis Research Unit, National Institute for Health and Medical Research (INSERM), at the Pitié-Salpétrière University Hospital in Paris, France, and Past-President of the European Atherosclerosis Society (EAS). As President of EAS from 2009 to 2013, he actively supported the development of new Joint Guidelines for the Management of Dyslipidemia with the European Society of Cardiology. Together with Prof Henry Ginsberg, he spearheads the EAS Consensus Panel initiatives and Consensus Papers; this initiative has focussed to date on Lipoprotein Lp(a), on atherogenic high triglyceride / low HDL dyslipidemia as a major cardiovascular risk factor, on the underdiagnosis and undertreatment of familial hypercholesterolemia, on homozygous familial hypercholesterolemia, on the genetics of hypertriglyceridemic states, and on plant sterols and stanols in the management of dyslipidemia and prevention of cardiovascular disease. These Consensus Paper publications have achieved worldwide visibility. In 2015, an EAS Consensus Paper focussed on statin-associated muscle symptoms has appeared; the third paper in the series on familial hypercholesterolemia, focussed on children and adolescents, is in press.
Professor Chapman undertook his undergraduate studies at Aberdeen University and the Middlesex Hospital Medical School, University of London. He subsequently trained in cardiovascular lipidology at the Cardiovascular Research Institute of the University of California Medical Center, San Francisco, and at the Gladstone Foundation for Cardiovascular Disease in the same city.
John Chapman is Associate European Editor of “Pharmacology and Therapeutics”, and a member of the Editorial Board of “Arteriosclerosis, Thrombosis and Vascular Biology”, “Atherosclerosis”, “Vascular Pharmacology”and “Future Lipidology”. He has authored numerous publications and book chapters, and has presented plenary conferences worldwide as part of his dedication to international educational initiatives in cardiovascular disease. In 2012, an authoritative treatise on High Density Lipoproteins, entitled “HDL : Structure, Metabolism, Function and Therapeutics” and co-authored by Dr A. Kontush and Prof Chapman, was published by Wiley.
In 2009, he received a Distinguished Career Award from the International Atherosclerosis Society for his contributions to the field of HDL biology. In 2011, John chaired the Gordon Research Conference on Atherosclerosis in Newport , RI, USA, and in 2010 and 2011, was awarded Prizes for Scientific Excellence by INSERM. Prof Chapman was Laureate of the European Lipid Science Award for 2014. He is Co-Chair of the PCSK9 Education and Research Forum. John is the 2015 Laureate of the Antonio M. Gotto Jr Award in Atherosclerosis Research from the International Atherosclerosis Society.
Present research interests are focussed on (i) the intravascular metabolism and pharmacotherapeutic modulation of atherogenic apoB-containing lipoproteins, and (ii) the structure, molecular composition and functionality of HDL particle subpopulations in the atherogenic dyslipidemias, and (iii) the development of new anti-atherosclerotic therapeutics for the prevention of cardiovascular disease.